LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

LLY

726.08

-2.8%↓

JNJ

153.46

-0.08%↓

ABBV

181.73

-1.73%↓

NVO

68.16

+0.29%↑

UNH

303.18

-5.79%↓

Search

Hutchison China MediTech Ltd ADR

Ouvert

SecteurSoins de santé

13.25 0.23

Résumé

Variation du prix de l'action

24h

Actuel

Min

13.09

Max

13.5

Chiffres clés

By Trading Economics

Revenu

-6.9M

6M

Ventes

9.4M

162M

P/E

Moyenne du Secteur

69.6

56.602

Marge bénéficiaire

3.676

Employés

1,811

EBITDA

5.6M

-5M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+57.12% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-183M

2.5B

Ouverture précédente

13.02

Clôture précédente

13.25

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 mai 2025, 20:54 UTC

Acquisitions, Fusions, Rachats

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mai 2025, 20:50 UTC

Résultats

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mai 2025, 23:48 UTC

Acquisitions, Fusions, Rachats

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mai 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mai 2025, 23:39 UTC

Market Talk

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mai 2025, 23:08 UTC

Market Talk

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mai 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mai 2025, 22:44 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 mai 2025, 22:20 UTC

Actualités

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mai 2025, 22:00 UTC

Résultats

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q EPS 10c >JHX

20 mai 2025, 21:44 UTC

Résultats

James Hardie Industries 4Q Sales $972M >JHX

20 mai 2025, 20:52 UTC

Actualités

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mai 2025, 20:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2025, 20:52 UTC

Market Talk

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mai 2025, 20:30 UTC

Acquisitions, Fusions, Rachats

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mai 2025, 20:28 UTC

Acquisitions, Fusions, Rachats

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mai 2025, 20:23 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Adj EPS BRL2.29 >XP

20 mai 2025, 20:22 UTC

Résultats

XP 1Q Rev BRL4.345B >XP

20 mai 2025, 20:21 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mai 2025, 20:20 UTC

Actualités

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mai 2025, 20:19 UTC

Acquisitions, Fusions, Rachats

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mai 2025, 20:11 UTC

Actualités

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mai 2025, 20:09 UTC

Résultats

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Comparaison

Variation de prix

Hutchison China MediTech Ltd ADR prévision

Objectif de Prix

By TipRanks

57.12% hausse

Prévisions sur 12 Mois

Moyen 20.85 USD  57.12%

Haut 27 USD

Bas 14.7 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

14.24 / 14.78Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.